Maravai Lifesciences Holdings Inc (MRVI)vsRegeneron Pharmaceuticals Inc (REGN)
MRVI
Maravai Lifesciences Holdings Inc
$6.59
-3.94%
HEALTHCARE · Cap: $2.47B
REGN
Regeneron Pharmaceuticals Inc
$738.34
+6.17%
HEALTHCARE · Cap: $68.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 7187% more annual revenue ($14.92B vs $204.73M). REGN leads profitability with a 29.6% profit margin vs -51.1%. REGN earns a higher WallStSmart Score of 64/100 (C+).
MRVI
Avoid31
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MRVI.
Margin of Safety
+50.0%
Fair Value
$1334.57
Current Price
$738.34
$596.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 40.5% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Operating margin of 1.1%
Elevated debt levels
Weak financial health signals
ROE of -49.4% — below average capital efficiency
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRVI
The strongest argument for MRVI centers on Revenue Growth. Revenue growth of 40.5% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : MRVI
The primary concerns for MRVI are Operating Margin, Debt/Equity, Piotroski F-Score.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
MRVI profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
MRVI carries more volatility with a beta of 0.65 — expect wider price swings.
MRVI is growing revenue faster at 40.5% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 31/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Maravai Lifesciences Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?